

Efficacy Study of a new anticoagulant drug

You are developing a new anticoagulant drug or reversal agent and want to evaluate its impact on coagulation and hemostasis in a comprehensive approach?

QUALIblood provides a comprehensive analytical package to evaluate the efficacy of your product from the early preclinical stage up to the late clinical phases.



Traditional automated hemostasis and coagulation assays

PT/INR

aPTT

TT

ACT

Anti-Xa activity

Fibrinogen (Clauss method or PT-derived)

ROTEM

Antithrombin III



Global coagulation evaluation

Thrombin generation assay



M Global Fibrinolyse evaluation


Fibwave (in house kinetic assay)

D Dimer



Specific hemostasis and coagulation assays (on demand)

Whole blood clotting time Homemade ACT



Contact us if you need additional information, have specific demand or need a quotation: contact@qualiblood.eu

